Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMV-specific cytotoxic T lymphocytes
- Development stage
- Unknown
- Lead developer
- Kalaris Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CMV-specific cytotoxic T lymphocytes (CMV-CTL) are an adoptive cellular immunotherapy developed by University Hospital Birmingham for the prevention and treatment of cytomegalovirus (CMV) infection in patients undergoing allogeneic hematopoietic stem cell transplantation (SCT). Following SCT, patients are severely immunocompromised and at high risk for CMV reactivation, which can lead to significant morbidity and mortality. This therapy involves the infusion of T cells specifically primed to recognize and eliminate CMV-infected cells, thereby restoring the recipient's cellular immunity against the virus. In clinical trials, these cells are typically selected from the stem cell donor or a third-party bank to provide immediate antiviral protection while the patient's own immune system recovers.
- Other names
- CMV-CTLadoptive immunotherapyCMV-specific T-lymphocyte infusioncytomegalovirus-specific cytotoxic T lymphocytesadoptive immunotherapy-University Hospital Birmingham-cytomegalovirus infection
02
Targets
CMV-HLA-II (Cytomegalovirus antigen-HLA class II complex)pMHC (Peptide-MHC complex family)pp65/HLA-A*02:01 (CMV pp65 peptide-HLA-A*02:01 complex)
Beyond the preview
Go deeper on CMV-specific cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMV-specific cytotoxic T lymphocytes.